The Readout Loud
314: JD Vance's biotech ties, Cassava resignations, and insulin shortages
This episode isn’t summarized yet
Create a free account and summarize it. In a few minutes you’ll have the key takeaways and a section-by-section summary.
Show notes
Our Washington correspondent Sarah Owermohle joins us to talk about how JD Vance, Donald Trump's newly announced running mate, could influence health policy if Trump wins the election. We also discuss the latest news in the biopharma industry, including the latest developments in the ongoing controversy surrounding Cassava’s Alzheimer’s drug, shortages of insulin as Novo Nordisk and Eli Lilly turn their focus toward GLP-1 drugs, and a shakeup in leadership at Gilead.